The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections
Abstract
Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous (RSV-IGIV) are licensed by the Food and Drug Administration for use in preventing severe respiratory syncytial virus (RSV) infections in high-risk infants, children younger than 24 months with chronic lung disease (formerly called bronchopulmonary dysplasia), and certain preterm infants. This report summarizes the clinical trial information on which the guidance in the accompanying policy statement for administering RSV prophylaxis to certain children with a history of preterm birth, chronic lung disease, or congenital heart disease is based. On the basis of results of a recently completed clinical trial, palivizumab is appropriate for infants and young children with hemodynamically significant congenital heart disease. RSV-IGIV should not be used in children with hemodynamically significant heart disease. Palivizumab is preferred for most high-risk infants and children because of ease of intramuscular administration. Monthly administration of palivizumab during the RSV season results in a 45% to 55% decrease in the rate of hospitalization attributable to RSV. Because of the large number of infants born after 32 to 35 weeks’ gestation and because of the high cost, immunoprophylaxis should be considered for this category of preterm infants only if 2 or more risk factors are present.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The IMpact-RSV Study Group (1998) · Pediatrics · doi:10.1542/peds.102.3.531 · Cited by 1,961
Feltes, T. F., Cabalka, A. K., Meissner, H. C., Piazza, F. M., Carlin, D. A., Top, F. H., Connor, E. M., Sondheimer, H. M., & for the Cardiac Synagis Study Group (2003) · The Journal of Pediatrics · doi:10.1067/s0022-3476(03)00454-2 · Cited by 824
Self-citationGroothuis, J. R., Simoes, E., Levin, M. J., Hall, C. B., Long, C. E., Rodriguez, W. J., Arrobio, J., Meissner, H. C., Fulton, D. R., Welliver, R. C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199311183292102 · Cited by 744
Self-citationJohnson, S., Oliver, C., Prince, G. A., Hemming, V. G., Pfarr, D. S., Wang, S., Dormitzer, M., O'Grady, J., Koenig, S., Tamura, J. K., et al. (1997) · The Journal of Infectious Diseases · doi:10.1086/514115 · Cited by 641
The PREVENT Study Group (1997) · Pediatrics · doi:10.1542/peds.99.1.93 · Cited by 450
Committee on Infectious Diseases and Committee on Fetus and Newborn (1998) · Pediatrics · doi:10.1542/peds.102.5.1211 · Cited by 408
Dankner, W. M. (1997) · Clinical Pediatrics · doi:10.1177/000992289703601013 · Cited by 313
Red Book: 2012 Report of the Committee on Infectious Diseases
Pickering, L. K. (2003) · Cited by 256
Committee on Infectious Diseases and Committee on Fetus and Newborn (2003) · Pediatrics · doi:10.1542/peds.112.6.1442 · Cited by 252
SIVA SUBRAMANIAN, K. N., WEISMAN, L. E., RHODES, T., ARIAGNO, R., SÁNCHEZ, P. J., STEICHEN, J., GIVNER, L. B., JENNINGS, T. L., TOP, F. H., CARLIN, D., et al. (1998) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199802000-00006 · Cited by 226
Cited by
Protein Therapeutics: A Summary and Pharmacological Classification
Leader, B., Baca, Q. J., & Golan, D. E. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2399 · Cited by 2,161
“Patients at high-risk for severe respiratory syncytial virus (RSV) infection, one of the leading causes of hospital admissions for paediatric respiratory illness, are given a recombinant monoclonal antibody, palivizumab, which binds to the RSV F protein and thereby directs the immune-mediated clearance of the virus fr…”
BackgroundCOMMITTEE ON INFECTIOUS DISEASES AND BRONCHIOLITIS GUIDELINES COMMITTEE, Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Jackson, M. A., Maldonado, Y. A., Murray, D. L., Orenstein, W. A., Rathore, M. H., et al. (2014) · Pediatrics · doi:10.1542/peds.2014-1665 · Cited by 771
Self-citationter Meulen, J., van den Brink, E. N., Poon, L. L. M., Marissen, W. E., Leung, C. S. W., Cox, F., Cheung, C. Y., Bakker, A. Q., Bogaards, J. A., van Deventer, E., et al. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030237 · Cited by 612
Hospital Discharge of the High-Risk Neonate
Committee on Fetus and Newborn (2008) · Pediatrics · doi:10.1542/peds.2008-2174 · Cited by 537
Delgado, M. F., Coviello, S., Monsalvo, A. C., Melendi, G. A., Hernandez, J. Z., Batalle, J. P., Diaz, L., Trento, A., Chang, H.-Y., Mitzner, W., et al. (2009) · Nature Medicine · doi:10.1038/nm.1894 · Cited by 500
Metadata
- Authors
- Meissner, H. C., Long, S. S., & Committee on Infectious Diseases, A. C. O. F. A. N.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2003-12-01
- Volume
- 112
- Issue
- 6
- Pages
- 1447-1452
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W2154581256
- Cited by
- 324
- References
- 19
- FWCI
- 13.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections. https://app.cochat.ai/papers/10.1542/peds.112.6.1447
- The paper
- Meissner, H. C., Long, S. S., & Committee on Infectious Diseases, A. C. O. F. A. N. (2003). Revised Indications for the Use of Palivizumab and Respiratory Syncytial Virus Immune Globulin Intravenous for the Prevention of Respiratory Syncytial Virus Infections. Pediatrics. https://doi.org/10.1542/peds.112.6.1447
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.